Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile

Journal of Neural Transmission

Volumn 111, Issue 2, 2004, Pages 113-126

  Bartoszyk, G D ^a   Van Amsterdam, C ^a   Greiner, H E ^a   Rautenberg, W ^a   Russ, H ^a   Seyfried, C A ^a  

^a MERCK KGAA   (Germany)

Author keywords

Dopamine ligand; Dyskinesia; Extrapyramidal movement disorders; Neurotransmitter turnover; Parkinson's disease; Sarizotan; Serotonin 5HT1A agonist

Indexed keywords

5 HYDROXYTRYPTOPHAN; CYCLIC AMP; DOPA; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; PARTIAL AGONIST; RESERPINE; SARIZOTAN; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN STEM INJURY; CELL LINE; CIRCLING BEHAVIOR; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DYSKINESIA; GUINEA PIG; IC 50; ILEUM CONTRACTION; MALE; NEUROCHEMISTRY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; STIMULATION; SUBSTANTIA NIGRA;

ANIMALS; ANTIPARKINSON AGENTS; BRAIN; CATTLE; CHO CELLS; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; GUINEA PIGS; HUMANS; LIGANDS; MALE; ORGANIC CHEMICALS; PROTEIN BINDING; RATS; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, DOPAMINE; SEROTONIN AGONISTS; SWINE;

EID: 1442314727     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00702-003-0094-7     Document Type: Article

References (61)

1. Ahlskog JE, Muenter MD (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16: 448-458
2. th American Academy of Neurology Meeting, Honolulu
3. 1A agonistic properties. Soc Neurosci Abstr 23: 530 (#207.5)
4. 1A receptor agonist and dopamine receptor ligand. 2. Behavioural profile. J Neural Transm (in preparation)
5. 3 receptor function. Nature Med 9: 762-767
6. 1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 57: 1829-1834
7. 2 antagonistic activity. Soc Neurosci Abstr 22: 841 (#334.1)
8. Casey DE (1991) Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophr Res 4: 109-120
9. Casey DE (1993) Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in nonhuman primates. Psychopharmacology 112 [Suppl 1]: S55-S59
10. Chase TN (1998) Levodopa therapy: consequences of the nonphysiologic replacement of dopamine.Neurology 50 [Suppl 5]: S17-S25
11. 3H]5-methoxy-3-(di-n-propylamino)-chroman. Eur J Pharmacol 140: 143-155
12. Costall B, Fortune DH, Naylor RJ, Marsden CD, Pycock C (1975) Serotonergic involvement with neuroleptic catalepsy. Neuropharmacology 14: 859-868
13. 2 dopamine receptor occupancy. Prog Neuropsychopharmacol Biol Psychiatry 25: 573-590
14. 1A receptor-mediated inhibition of forskolin-stimulated adenylate cyclase activity in guinea pig and rat hippocampal membranes. J Pharmacol Exp Ther 238: 248-253
15. 1A agonist. J Pharmacol Exp Ther 267: 58-71
16. 1A receptors. Br J Pharmacol 86: 601P
17. Fuller RW, Perry KW (1989) Effects of buspirone and its metabolite, 1-(2-pyrimidinyl)piperazine, on brain monoamines and their metabolites in rats. J Pharmacol Exp Ther 248: 50-56
18. 3H]-DOPA in various regions of the brain. J Neurochem 13: 655-669
19. 4 receptors in guinea pig and rat brain. Br J Pharmacol 109: 618-624
20. Hadj-Tahar A, Belanger N, Bangassoro E, Gregoire L, Bedard PJ (2000) Antidyskinetic effect of JL-18, a clozapine analog, in parkinsonian monkeys. Eur J Pharmacol 399: 183-186
21. 1A agonists with potential anxiolytic properties. J Pharmacol Exp Ther 246: 745-752
22. 1 dopamine receptors in rat striatum. Eur J Pharmacol 121: 31-38
23. Hicks PB (1990) The effect of serotonergic agents on haloperidol-induced catalepsy. Life Sci 47: 1609-1615
24. Hjorth S, Carlsson A, Magnusson T, Arvidsson LE (1987) In vivo biochemical characterization of 8-OH-DPAT: evidence for 5-HT receptor selectivity and agonist action in the rat CNS. In: Dourish CT (ed) Brain 5HT1A receptors. VCH Verlagsgesellschaft, Weinheim, pp 94-105
25. 125-iodocyanopindolol. Eur J Pharmacol 118: 1-12
26. Jellinger KA (2002) Recent developments in the pathology of Parkinson's disease. J Neural Transm [Suppl] 62: 347-376
27. Jones BJ, Blackburn TP (2002) The medical benefit of 5-HT research. Pharmacol Biochem Behav 71: 555-568
28. Klockow M, Greiner HE, Haase A, Schmitges CJ, Seyfried C (1986) Studies on receptor profile of Bisoprolol. Drug Res 36: 197-200
29. 6 receptor. J Neurochem 66: 47-56
30. Kulkarni SK, Naidu PS (2001) Animal models of tardive dyskinesia - a review. Indian J Physiol Pharmacol 45: 148-160
31. Kulkarni SK, Naidu PS (2003) Pathophysiology and drug therapy of tardive dyskinesia: current concepts and future perspectives. Drugs Today 39: 19-49
32. Largent BL, Gundlach AL, Snyder SH (1986) Sigma receptors on NCB-20 hybrid neurotumor cells labeled with (+)[3H]SKF 10,047 and (+)[3H]3-PPP. Eur J Pharmacol 124: 183-187
33. Llorca PM, Chereau I, Bayle FJ, Lancon C (2002) Tardive dyskinesias and antipsychotics: a review. Eur Psychiatry 17: 129-138
34. 1A receptor agonism of 8-OH-DPAT and EMD 128130 to the regulation of haloperidol-induced muscle rigidity in rats. Neuropharmacology 45: 1057-1069
35. 3 receptors involved? J Neural Transm 106: 1063-1073
36. McMillen BA, Scott SM, Davanzo EA (1988) Reversal of neuroleptic-induced catalepsy by novel arylpiperazine anxiolytic drugs. J Pharm Pharmacol 40: 885-887
37. McPherson GA (1983) A practical computer-based approach to the analysis of radioligand binding experiments. Comput Prog Biomed 17: 107-114
38. 3 receptor antagonist, (+)-S 14297, blocks the cataleptic properties of haloperidol in rats. Eur J Pharmacol 321: R7-R9
39. Muscettola G, Barbato G, Pampallona S, Casiello M, Bollini P (1999) Extrapyramidal syndromes in neuroleptic-treated patients: prevalence, risk factors, and association with tardive dyskinesia. J Clin Psychopharmacol 19: 203-208
40. Northoff G (2002) Catatonia and neuroleptic malignant syndrome: psychopathology and pathophysiology. J Neural Transm 109: 1453-1467
41. Olanow CW, Damier P, Chicago CG, Mueller T, Nutt J, Rascol O, Russ H (2002) A prospective, 3-month multicenter, open label dose-rising study of the effect of sarizotan on dyskinesia in Parkinson's disease. Mov Disord 17 [Suppl 5]: S327
42. Pazos A, Hoyer D, Palacios JM (1985) The binding of serotonergic ligands to the porcine chorioid plexus: characterization of a new type of serotonin recognition site. Eur J Pharmacol 106: 539-546
43. 1D binding sites in human brain membranes. Synapse 3: 61-66
44. Rajput AH, Fenton ME, Birdi S, Macaulay R, George D, Rozdilsky B, Ang LC, Senthilselvan A, Hornykiewicz O (2002) Clinical-pathological study of levodopa complications. Mov Disord 17: 289-296
45. Rascol O, Fabre N (2001) Dyskinesia: L-dopa-induced and tardive dyskinesia. Clin Neuropharmacol 24: 313-323
46. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342: 1484-1491
47. Rosengarten H, Bartoszyk GD, Quartermain D, Lin Y (2003) The effect of chronic administration of sarizotan on haloperidol induced repetitive jaw movements in rat model of tardive dyskinesia. Psychopharmacology (submitted)
48. Sacristan JA, Gomez JC, Montejo AL, Vieta E, Gregor KJ (2000) Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina. Clin Ther 22: 583-599
49. 2A receptors in antipsychotic and anticataleptic action. J Psychopharmacol 11: 15-17
50. 2-autoreceptor agonists, with special reference to indolylbutylamines. Drugs Future 15: 819-832
51. Seyfried CA, Tobler P (1991) Total versus unspecific binding: standardization of receptor-ligand binding assays. Drug Metabol Drug Interact 9: 149-160
52. Seyfried CA, Adam G, Greve T (1986) An automated direct-injection HPLC-method for the electrochemical/fluorimetric quantitation of monoamines and related compounds optimized for the screening of large numbers of animals. Biomed Chromatogr 1: 78-88
53. Seyfried CA, Greiner HE, Haase AF (1989) Biochemical and functional studies on EMD 49 980: a potent, selectively presynaptic D-2 dopamine agonist with actions on serotonin systems. Eur J Pharmacol 160: 31-41
54. 3H] ethylketocyclazocine, mu, kappa, delta, and phencyclidine binding sites in guinea pig membranes. Eur J Pharmacol 109: 33-41
55. Tolwani RJ, Jakowec MW, Petzinger GM, Green S, Waggie K (1999) Experimental models of Parkinson's disease: insights from many models. Lab Anim Sci 49: 363-371
56. Ungerstedt U, Arbuthnott GW (1970) Quantitative recording of rotational behaviour in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. Brain Res 24: 485-493
57. 7 receptors: current knowledge and future prospects. Trends Pharmacol Sci 21: 70-77
58. Wadenberg ML (1996) Serotonergic mechanisms in neuroleptic-induced catalepsy in the rat. Neurosci Biobehav Rev 20: 325-339
59. 2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology 150: 422-429
60. Wagner ML, Fedak MN, Sage JI, Mark MH (1996) Complications of disease and therapy: a comparison of younger and older patients with Parkinson's disease. Ann Clin Lab Sci 26: 389-395
61. 7 serotonin receptors. Pol J Pharmacol 54: 327-341